Wird geladen...
Complementing the Cancer-Immunity Cycle
Reactivation of cytotoxic CD8(+) T-cell responses has set a new direction for cancer immunotherapy. Neutralizing antibodies targeting immune checkpoint programmed cell death protein 1 (PD-1) or its ligand (PD-L1) have been particularly successful for tumor types with limited therapeutic options such...
Gespeichert in:
| Veröffentlicht in: | Front Immunol |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Frontiers Media S.A.
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6473060/ https://ncbi.nlm.nih.gov/pubmed/31031765 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2019.00774 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|